InterMune's P2P Acquisition

InterMune raised a round of funding on August 24, 2014. Investors include Roche Holding.

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, the company is foc…

Articles about InterMune's P2P Acquisition: